SignaCor Therapeutics
Clinical-stage drug development company advancing treatments for hypertrophic cardiomyopathy and cardiovascular health.
About
SignaCor Therapeutics is a clinical-stage drug development company spun out from Queen's University Belfast. They are developing first-in-class therapies for symptomatic hypertrophic cardiomyopathy (HCM) that target underlying disease pathology to reverse heart damage and improve patient outcomes.
Show 6 more similar companies
Similar companies
Digital pathology imaging technology and AI-driven precision pathology software.
Shares HealthTech, Biotechnology
Advancing the next phase of its precision health AI strategy.
Shares HealthTech, Biotechnology
Epitel develops AI-driven wireless brain health technologies for remote EEG monitoring, improving diagnosis and management of neurological conditions like epilepsy.
Shares HealthTech, Biotechnology
Develops in-vitro diagnostic platforms for rapid antimicrobial susceptibility testing.
Shares HealthTech, Biotechnology
AI-powered breast cancer detection and risk assessment solutions.
Shares HealthTech, Biotechnology
AI-driven diagnostics that convert medical images into actionable genomic insights for faster cancer treatment decisions.
Shares HealthTech, Biotechnology
Signals agent
Reach companies that have budget right now
Every week the agent finds companies in your market that just got money or started hiring to spend it, and the person to talk to. You choose who to reach; nothing is sent for you.
- Just raised a roundFresh budget, the week it lands
- Hiring sales and marketingGo-to-market roles mean money to spend
- Hiring fastA jump in open roles across the company
- In the newsLaunches and announcements worth a message
- The decision makerWho to contact, with a message you can edit
Is your startup an alternative to SignaCor Therapeutics?
People comparing tools land here. Get listed beside these.
All funding rounds
Get notified when SignaCor Therapeutics changes
Used SignaCor Therapeutics? Write a review and get $5 in credits
Your first review on StartupHub.ai adds 1,250 credits to your account. Spend them on:
- Email finder
- Market Map Maker
- Agent Readiness scans
- Deep intel
- Tech stack scans
Frequently asked
Is SignaCor Therapeutics growing?
Yes, fast. Our data shows it raised $315K in a Seed in March 2026.
Who owns SignaCor Therapeutics?
SignaCor Therapeutics is privately held, owned by its founders and investors. Investors on record include ZINC. Exact stakes are not public.
Are there companies like SignaCor Therapeutics?
Yes. We list 6 companies like SignaCor Therapeutics, including Grundium, Verily and Epitel, Inc..
How much funding has SignaCor Therapeutics raised?
SignaCor Therapeutics has raised a total of $315K in funding. The most recent round on record is Seed.
SEC filings, insider activity, nonprofit links and pay benchmarks for SignaCor Therapeutics:
Company details: from public sources. Funding: 1 round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
Categories
Max Agent
Let Max Agent watch SignaCor Therapeutics and its market for you
New competitors, funding rounds, pricing and product changes, and where you show up in AI answers, in one weekly report.
Free week
Starter listings, once
AI answers checked
Daily for 7 days
ChatGPT
Perplexity
Max Agent
$79 a month, or $9.99 with our badge on your site
AI answers checked
Every week
ChatGPT
Claude
Perplexity
Gemini

